Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of two injectable dermal fillers from the Juvéderm product line—Juvéderm Volbella XC and Juvéderm Ultra XC. Both are hyaluronic acid-based gels formulated with lidocaine for local anesthesia. - **Juvéderm Volbella XC** is designed for lip augmentation, correction of perioral lines (lipstick lines), and improvement of infraorbital hollowing (undereye hollows). It uses VYCROSS technology to create a smooth gel that integrates well into tissue, providing subtle volume and smoothing effects that can last up to one year[2][3][4][5][6]. - **Juvéderm Ultra XC** is indicated for injection into the lips and perioral area for lip augmentation in adults over 21 years old. It provides more robust volumization compared to Volbella, making it suitable for patients seeking fuller lips or correction of moderate facial wrinkles[2][5]. Both products are FDA-approved as temporary fillers; they work by adding volume through crosslinked hyaluronic acid, which attracts water molecules and integrates into the skin matrix. Lidocaine reduces discomfort during injection.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on volbella + juvederm ultra xc.